A novel liposome incorporating the cell-penetrating peptide CGYKK linked to cholesterol maintained approximately 90% mRNA encapsulation after six months at refrigerator temperature, offering a more stable alternative to current lipid nanoparticle mRNA delivery systems.
~90% encapsulation at 6 monthsThe peptide-cholesterol liposome maintained approximately 90% mRNA encapsulation after six months stored at 4°C — standard refrigerator temperature — addressing the critical cold-chain limitation of current mRNA vaccine technology.
What the researchers found
The novel chol-CGYKK molecule was successfully synthesized by connecting the peptide CGYKK to cholesterol via a disulfide linker. When incorporated into cationic liposomes carrying spike protein mRNA, the system maintained approximately 90% encapsulation rate after six months at 4°C — addressing a critical stability limitation of current LNP-mRNA systems.
Among four formulations tested with different excipient ratios, formulated sample 1 showed the highest spike protein expression. Its transfection efficiency reached 66.7% compared to the commercial transfection reagent Lipofectamine 2000.
Safety evaluation showed no toxic effects from either the CGYKK peptide or the complete mRNA vaccine liposomes. In vivo studies demonstrated that the vaccine triggered an immune response, though it was not yet as strong as the LNP-based comparator group.
Why it matters
Current mRNA vaccines require ultra-cold storage (-20°C to -80°C), creating massive logistical challenges for global distribution. A delivery system that maintains 90% encapsulation at standard refrigerator temperature (4°C) for six months could dramatically simplify vaccine storage and distribution, particularly in developing countries lacking cold-chain infrastructure. The cell-penetrating peptide approach offers a fundamentally different design strategy from current LNP technology.
How the study worked
The CGYKK peptide was synthesized using solid-phase peptide synthesis and conjugated to cholesterol through a disulfide linker. Four liposome formulations with varying excipient proportions were prepared by freeze-drying cationic liposomes loaded with SARS-CoV-2 spike protein mRNA. Physical characterization was performed using transmission electron microscopy, atomic force microscopy, and scanning electron microscopy. Stability was assessed by measuring encapsulation rate over six months at 4°C. Biological activity was evaluated through cellular uptake studies, transfection efficiency compared to Lipofectamine 2000, protein expression measurement, safety/toxicity assessment, and in vivo immune response in animals.
What this study cannot tell us
The in vivo immune response was weaker than the LNP comparator group, meaning this system is not yet competitive with existing technology in terms of efficacy. Transfection efficiency of 66.7% relative to Lipofectamine 2000 (a research-grade reagent, not a clinical product) is modest. The study does not provide detailed quantitative immune response data or compare to clinically approved LNP formulations. Long-term animal safety data beyond initial screening is not reported. The specific animal model and group sizes are not detailed in the abstract.
How to read the evidence
This is an early-stage preclinical study demonstrating proof of concept for a new delivery technology. While the stability data is promising and the system showed in vivo immune responses, the efficacy was lower than the LNP comparator, and detailed quantitative data on immune outcomes is limited in the abstract.
When this study was published
Published in 2023, this study is recent and addresses an ongoing challenge in the rapidly evolving mRNA therapeutics field. The technology may have been further developed since publication.
The bigger picture
The mRNA vaccine revolution sparked by COVID-19 revealed that delivery technology is as important as the mRNA itself. While lipid nanoparticles enabled the first mRNA vaccines, their stability limitations remain a bottleneck. Cell-penetrating peptides represent a promising alternative delivery strategy that could improve stability while maintaining the ability to get mRNA into cells. This study is part of a broader effort to develop next-generation mRNA delivery platforms that are more practical for global health applications.
Questions still open
- Can the immune response be improved through further optimization of the liposome formulation while maintaining the stability advantage?
- Would this peptide-cholesterol liposome system work equally well for delivering other mRNA cargoes beyond the SARS-CoV-2 spike protein?
- How does the cost of manufacturing this peptide-based system compare to standard LNP production?
Common questions
What is a cell-penetrating peptide and how does it help deliver mRNA?
Why is mRNA vaccine storage stability such a big deal?
Read the original research
Synthesis of cell penetrating peptide sterol coupler and its liposome study on S-mRNA.
European journal of medicinal chemistry, 261, 115822
Citation
Li, Yuan; Ma, Wenlin; Su, Wen; Yan, Zhihong; Jia, Lin; Deng, Jie; Zhu, Ali; Xie, Yanbo; Li, Xinyi; Shao, Wanhui; Ma, Yuman; Che, Linze; Zhu, Tao; Wang, Haomeng; Li, Mingyuan; Yu, Peng. (2023). Synthesis of cell penetrating peptide sterol coupler and its liposome study on S-mRNA.. European journal of medicinal chemistry, 261, 115822. https://doi.org/10.1016/j.ejmech.2023.115822